Arcus Biosciences (NYSE:RCUS) Given New $25.00 Price Target at Morgan Stanley

Arcus Biosciences (NYSE:RCUS) had its price target lowered by Morgan Stanley from $36.00 to $25.00 in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other research firms have also weighed in on RCUS. Barclays raised their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Arcus Biosciences in a report on Thursday, November 7th. Finally, HC Wainwright reduced their price objective on shares of Arcus Biosciences from $20.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $29.50.

Arcus Biosciences Price Performance

Arcus Biosciences stock opened at $10.76 on Tuesday. Arcus Biosciences has a 52-week low of $10.63 and a 52-week high of $20.31. The firm has a fifty day moving average of $14.02 and a 200-day moving average of $15.56. The firm has a market capitalization of $984.21 million, a P/E ratio of -3.41 and a beta of 0.84. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08.

Insider Transactions at Arcus Biosciences

In other news, CFO Robert C. Goeltz II sold 3,594 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total value of $53,910.00. Following the transaction, the chief financial officer now directly owns 60,138 shares in the company, valued at approximately $902,070. This trade represents a 5.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 12.30% of the company’s stock.

Institutional Trading of Arcus Biosciences

A number of large investors have recently modified their holdings of RCUS. GSA Capital Partners LLP increased its holdings in shares of Arcus Biosciences by 17.8% in the 3rd quarter. GSA Capital Partners LLP now owns 187,415 shares of the company’s stock worth $2,866,000 after acquiring an additional 28,307 shares during the period. Quest Partners LLC increased its stake in Arcus Biosciences by 40,904.3% during the 3rd quarter. Quest Partners LLC now owns 9,431 shares of the company’s stock valued at $144,000 after buying an additional 9,408 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Arcus Biosciences by 25.1% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 931,048 shares of the company’s stock valued at $14,236,000 after buying an additional 186,750 shares during the period. Intech Investment Management LLC acquired a new position in Arcus Biosciences during the 3rd quarter valued at about $244,000. Finally, Massachusetts Financial Services Co. MA increased its stake in Arcus Biosciences by 39.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 80,889 shares of the company’s stock valued at $1,237,000 after buying an additional 22,716 shares during the period. Institutional investors and hedge funds own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.